Exome sequencing revealed comparable frequencies of RNF43 and BRAF mutations in Middle Eastern colorectal cancer.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
30 07 2022
Historique:
received: 09 12 2021
accepted: 26 07 2022
entrez: 30 7 2022
pubmed: 31 7 2022
medline: 3 8 2022
Statut: epublish

Résumé

Mutation-induced activation of Wnt-β Catenin signaling pathway is frequent in CRC. The E3 ubiquitin ligase, RNF43, has been reported to negatively regulate the Wnt signaling pathway and RNF43 mutations are frequently seen in CRC. However, its role in Middle Eastern CRC remains unclear. Therefore, we employed Exome and Sanger sequencing technology to assess the frequency of RNF43 mutations and its association with other clinico-pathological features in Middle Eastern CRC. RNF43 mutations were found in 5.9% (13/220) of CRC cases and was inversely correlated to APC and TP53 mutations. A strong association of RNF43 mutations with right sided and sporadic microsatellite instable (MSI) CRC was observed. No association was identified between RNF43 mutation and other clinico-pathological features including BRAF mutation, age, tumor histological subtype, tumor grade or patients' prognosis. Multivariate logistic regression analysis revealed that MSI status and wild type APC were independent predictor of RNF43 mutation. We conclude that RNF43 mutations occur in Middle Eastern CRC at comparable frequencies with BRAF mutations and represent a distinct molecular subtype which further enhances our understanding of how different mutational subsets of Wnt tumor suppressor genes link to distinct tumor characteristics, which might be considered for treatment strategies for CRC patients.

Identifiants

pubmed: 35907983
doi: 10.1038/s41598-022-17449-9
pii: 10.1038/s41598-022-17449-9
pmc: PMC9338933
doi:

Substances chimiques

RNF43 protein, human EC 2.3.2.27
Ubiquitin-Protein Ligases EC 2.3.2.27
BRAF protein, human EC 2.7.11.1
Proto-Oncogene Proteins B-raf EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

13098

Informations de copyright

© 2022. The Author(s).

Références

Oncotarget. 2018 Dec 18;9(99):37319-37332
pubmed: 30647872
Hum Pathol. 2015 Nov;46(11):1640-6
pubmed: 26297255
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Mol Cancer. 2014 Jul 08;13:168
pubmed: 25005754
J Clin Pathol. 2018 Jan;71(1):1-6
pubmed: 29018044
Int J Cancer. 2016 Sep 1;139(5):1091-7
pubmed: 27082205
Gut. 2017 Sep;66(9):1645-1656
pubmed: 27329244
Ann Saudi Med. 2018 Nov-Dec;38(6):427-432
pubmed: 30531177
Oncotarget. 2017 Dec 12;9(1):969-981
pubmed: 29416670
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Oncotarget. 2016 Oct 25;7(43):70589-70600
pubmed: 27661107
J Clin Oncol. 2004 Dec 15;22(24):4934-43
pubmed: 15611508
Nat Genet. 2014 Dec;46(12):1264-6
pubmed: 25344691
Cancer Cell. 2018 Jan 8;33(1):125-136.e3
pubmed: 29316426
Nat Rev Cancer. 2017 Feb;17(2):79-92
pubmed: 28050011
Nature. 2012 Aug 30;488(7413):665-9
pubmed: 22895187
BMJ Open Gastroenterol. 2019 Jul 24;6(1):e000317
pubmed: 31413858
Oncol Rep. 2020 Jun;43(6):1853-1862
pubmed: 32236609
Fam Cancer. 2018 Jan;17(1):63-69
pubmed: 28573495
Bioinformatics. 2010 Mar 1;26(5):589-95
pubmed: 20080505
Int J Gen Med. 2020 Oct 29;13:977-990
pubmed: 33149661
Cancer. 2015 Jun 1;121(11):1762-71
pubmed: 25712738
J Pathol. 2016 Jun;239(2):133-8
pubmed: 26924569
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Cancer Cell Int. 2019 Dec 11;19:334
pubmed: 31866764
Clin Cancer Res. 2022 May 2;28(9):1863-1870
pubmed: 35254413
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Nat Rev Gastroenterol Hepatol. 2019 Dec;16(12):713-732
pubmed: 31455888
Gastroenterology. 2020 May;158(6):1520-1523
pubmed: 31982410
JAMA. 2011 Apr 27;305(16):1685-94
pubmed: 21521850
Curr Colorectal Cancer Rep. 2017 Apr;13(2):101-110
pubmed: 28413363
Nat Rev Cancer. 2021 Jan;21(1):5-21
pubmed: 33097916
Pathol Res Pract. 2019 Aug;215(8):152453
pubmed: 31122752
Oncogene. 2017 Mar;36(11):1461-1473
pubmed: 27617575
J Pers Med. 2021 Jan 26;11(2):
pubmed: 33530623
Oncologist. 2020 May;25(5):404-413
pubmed: 31848314

Auteurs

Abdul Khalid Siraj (AK)

Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, MBC#98-16, P.O. Box 3354, Riyadh, 11211, Saudi Arabia.

Rong Bu (R)

Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, MBC#98-16, P.O. Box 3354, Riyadh, 11211, Saudi Arabia.

Tariq Masoodi (T)

Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, MBC#98-16, P.O. Box 3354, Riyadh, 11211, Saudi Arabia.

Sandeep Kumar Parvathareddy (SK)

Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, MBC#98-16, P.O. Box 3354, Riyadh, 11211, Saudi Arabia.

Kaleem Iqbal (K)

Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, MBC#98-16, P.O. Box 3354, Riyadh, 11211, Saudi Arabia.

Wael Al-Haqawi (W)

Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, MBC#98-16, P.O. Box 3354, Riyadh, 11211, Saudi Arabia.

Hassan Al-Dossari (H)

Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, MBC#98-16, P.O. Box 3354, Riyadh, 11211, Saudi Arabia.

Saud Azam (S)

Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, MBC#98-16, P.O. Box 3354, Riyadh, 11211, Saudi Arabia.

Zeeshan Qadri (Z)

Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, MBC#98-16, P.O. Box 3354, Riyadh, 11211, Saudi Arabia.

Padmanaban Annaiyappanaidu (P)

Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, MBC#98-16, P.O. Box 3354, Riyadh, 11211, Saudi Arabia.

Fouad Al-Dayel (F)

Department of Pathology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Khawla Sami Al-Kuraya (KS)

Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Center, MBC#98-16, P.O. Box 3354, Riyadh, 11211, Saudi Arabia. kkuraya@kfshrc.edu.sa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH